drugset / Trial / NCT00370305

11ß-HSD1 and Metabolic Syndrome

NCT00370305

Phase 2 Completed 24 enrolled Charite University, Berlin, Germany
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the insulin sensitizing effects of rosiglitazone were accompanied by changes in 11ß-HSD1 expression and activity in different tissues. Furthermore the metabolic and hormonal effects of PPAR gamma stimulation by rosiglitazone will be analysed in several tissues.

Timeline

Start
2004-05
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosiglitazone Small molecule 89 mg Oral